Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

NCT01323920 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Lymphoma
Myelodysplastic Syndrome

Interventions

DRUG: Bortezomib
DRUG: Tacrolimus
DRUG: Methotrexate

Sponsor

Dana-Farber Cancer Institute